645 related articles for article (PubMed ID: 19060552)
1. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
2. Management of chronic allograft dysfunction by switch over to rapamycin.
Sundaram V; Abraham G; Fathima N; Sundaram V; Reddy YN; Mathew M; Sathiah V
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690
[TBL] [Abstract][Full Text] [Related]
3. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
4. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
5. Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen.
Yilmaz M; Nart A; Sen S; Tasli F; Uslu A; Hur E; Ozkahya M; Hoscoskun C; Toz H
Nephrology (Carlton); 2010 Sep; 15(6):653-8. PubMed ID: 20883287
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
7. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.
Stallone G; Infante B; Schena A; Battaglia M; Ditonno P; Loverre A; Gesualdo L; Schena FP; Grandaliano G
J Am Soc Nephrol; 2005 Dec; 16(12):3755-62. PubMed ID: 16236802
[TBL] [Abstract][Full Text] [Related]
9. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
10. Ten-year protocol biopsy findings of renal allografts in the calcineurin inhibitor era.
Okamoto M; Akioka K; Ushigome H; Higuchi A; Nobori S; Ogino S; Uryuhara K; Kaihara S; Hatta T; Urasaki K; Yoshimura N
Clin Transplant; 2006; 20 Suppl 15():16-9. PubMed ID: 16848870
[TBL] [Abstract][Full Text] [Related]
11. Evidence for immunosuppression in lung transplantation.
Hopkins PM; McNeil K
Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
[TBL] [Abstract][Full Text] [Related]
12. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
13. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
Gutiérrez MJ; González E; Andrés A; Morales JM
Transplant Proc; 2009; 41(6):2348-50. PubMed ID: 19715916
[TBL] [Abstract][Full Text] [Related]
15. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
Pontrelli P; Rossini M; Infante B; Stallone G; Schena A; Loverre A; Ursi M; Verrienti R; Maiorano A; Zaza G; Ranieri E; Gesualdo L; Ditonno P; Bettocchi C; Schena FP; Grandaliano G
Transplantation; 2008 Jan; 85(1):125-34. PubMed ID: 18192922
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
18. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus in renal transplantation.
Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]